Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Kreitman, Robert J.
Tiacci, Enrico
Andritsos, Leslie
Banerji, Versha
Barrientos, Jacqueline C.
Bhat, Seema A.
Blachly, James S. http://orcid.org/0000-0002-4275-5562
Broccoli, Alessandro http://orcid.org/0000-0001-5633-7313
Call, Timothy
Chihara, Dai http://orcid.org/0000-0002-1153-2294
Dearden, Claire
Demeter, Judit http://orcid.org/0000-0001-8745-0757
Dietrich, Sasha http://orcid.org/0000-0002-0648-1832
Else, Monica http://orcid.org/0000-0001-8578-4796
Epperla, Narendranath http://orcid.org/0000-0002-8216-3457
Falini, Brunangelo http://orcid.org/0000-0002-7198-5965
Forconi, Francesco http://orcid.org/0000-0002-2211-1831
Gladstone, Douglas E.
Gozzetti, Alessandro http://orcid.org/0000-0003-0769-6891
Iyengar, Sunil
Johnston, James B.
Jorgensen, Jeffrey http://orcid.org/0000-0002-1875-2986
Juliusson, Gunnar
Lauria, Francesco
Lozanski, Gerard
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Park, Jae H. http://orcid.org/0000-0002-2903-5130
Polliack, Aaron
Quest, Graeme
Robak, Tadeusz http://orcid.org/0000-0002-3411-6357
Rogers, Kerry A.
Saven, Alan
Seymour, John F. http://orcid.org/0000-0003-2188-6835
Tadmor, Tamar http://orcid.org/0000-0002-3435-8612
Tallman, Martin S.
Tam, Constantine S.
Thompson, Philip A. http://orcid.org/0000-0003-2086-6031
Troussard, Xavier
Zent, Clive S. http://orcid.org/0000-0001-6099-3313
Zenz, Thorsten http://orcid.org/0000-0001-7890-9845
Zinzani, Pier Luigi http://orcid.org/0000-0002-2112-2651
Wörmann, Bernhard http://orcid.org/0000-0003-2273-5502
Rai, Kanti http://orcid.org/0000-0002-5804-2823
Grever, Michael
Article History
Received: 18 September 2022
Revised: 14 November 2022
Accepted: 28 November 2022
First Online: 13 December 2022
Competing interests
: FR: Consultancy and Honoraria: Celgene, BMS, Amgen, Astellas, Xencor, Agios, AstraZeneca, Orsenix, Innate Pharma, Syros, Taiho, Novartis; Research Funding: BMS, Amgen, Xencor, Macrogenics, Orsenix, AbbVie, Taiho, Prelude, Astex. RK: Employment: National Institutes of Health and Regional Cancer Care Associates; Honoraria: PlatformQ, OncLive, Cure; Research Funding: Innate, AstraZeneca, Novartis, Genetech, Pfizer, Teva, Hairy Cell Leukemia Foundation; and Patents: Coinventor for NIH patent for Moxetumomab Pasudotox. EI: Consultant: Innate Pharma. Research funding: Roche. Travel cost: Shire. Holder of a patent on the use of mutant BRAF as HCL biomarker. Our research work in HCL is funded by the Hairy Cell Leukemia Foundation, the Leukemia and Lymphoma Society and the Associazione Italiana Ricerca sul Cancro (AIRC). LA: None. VB: VB serves on the advisory boards of Janssen, Astra Zeneca, AbbVie, and Beigene and has had research funding from CIHR, LLSC, CCMF, Roche, Janssen, and AbbVie. VB also received fees from BIOGEN for patented compounds unrelated to this study. JB: Research funding: AstraZeneca, Oncternal, TG therapeutics, Pharmacyclics/AbbVie; and Advisory Board: AstraZeneca, Pharmacyclics/AbbVie, Beigene, Genentech, Gilead, Innate. SB: Served on Advisory board for Pharmacyclics and Janssen, Beigene and AstraZeneca; Received honorarium from OncLive; and Received travel grant from Arqule. JB: Consulting and Advisory Board: AbbVie, AstraZeneca, INNATE Pharma, KITE Pharma; Research funding: MingSight Pharmaceuticals; and Patents and Intellectual Property: A leukemia diagnostic device (patent pending). AB: None reported. TC: None reported. DC: None reported. CD: Has been an advisor for Medimmune/ Innate Pharma (moxetumomab); Consulting/ Advisory board for AbbVie and Jansen. JD: Has participated in advisory committees in Hungary for Novartis, Bristol Myers Squibb, Amicus, Angelini, Pfizer, Amgen, Roche. SD: None reported. ME: None reported. BF: None reported. FF: Research Support/P.I.: CRUK, Blood Cancer UK; Consultancies: AstraZeneca, AbbVie, Janssen-Cilag, BC-Platform, Beigene; Speakers Bureau: AstraZeneca, AbbVie; and Honoraria: AstraZeneca, AbbVie. DG: None reported. AG: Honoraria: Jansenn and AbbVie. SI: Advisory and speaker fees: Gilead and Takeda; Advisory: Beigene; and Speaker fees: Janssen, Takeda and Gilead. JBJ: None reported. JJ: None reported. GJ: None reported. FL: None reported. GL: None reported. SP: Research funding to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator. Sameer A. Parikh has received honoraria for participation in consulting activities/advisory board meetings for Pharmacyclics, Merck, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Biotechnologies, and AbbVie (no personal compensation), and from DynaMed, Aptitude Health, Curio Science, and MedEd on the Go (with personal compensation). JP: Research funding from Genentech, Servier, Takeda, Fate Therapeutics and Amgen; Consulting fees from Servier, Amgen, AstraZeneca, Innate Pharma, Novartis, Kite Pharma, Takeda, Intellia, Kura Oncology, Pfizer, BMS, Curocel, Minerva, Autolus; serves on DSMB for Affyimmune and BrightPharma; serves on Scientific Advisory Board for Allogene and Artiva. AP: None reported. GQ: None reported. TR: Honoraria: Sandoz, BeiGene, AstraZeneca; Advisory/Consulting: Jannssen, AstraZeneca, Takeda, BeiGene; and Research Funding: AstraZeneca (ongoing), Acerta (ongoing), Janssen (ongoing). KAR: Research funding: Genentech, AbbVie, Novartis, and Janssen; Consulting: Acerta Pharma, AstraZeneca, Innate Pharma, Genentech, AbbVie, Pharmacyclics, and Beigene; and Travel funding: AstraZeneca. AS: None reported. JS: AbbVie: Advisory board, speakers’ bureau, research funding; Astra Zeneca: Advisory board; Celgene: Advisory board, speakers’ bureau, research funding, expert testimony; Genentech: Advisory board; Gilead: Advisory Board; Janssen: Advisory board, research funding; Mei Pharma: Advisory board; Morphosys, Advisory board; Roche, Advisory board, speakers’ bureau, research funding, expert testimony; Sunesis, Advisory board; Takeda, Advisory board. TT: Grant from Janssen; Advisory Board/Consulting: AbbVie, Janssen, Astra Zeneca, Roche, Novartis, Takeda, and Sanofi. MT: Research funding: AbbVie, Amgen, Biosight, Glycomimetics, Orsenix, Rafael; Advisory boards: Amgen, Daiichi-Sankyo, Innate pharmaceuticals, Jazz, Kahr, Kura, Novartis, Orsenix, Roche, Syros, Ipsen Biopharmaceuticals, and Oncolyze; and Royalties: UpToDate. CT: Honorarium: Beigene, Novartis, LOXO, AbbVie, Janssen; Research funding: Beigene, AbbVie, Janssen. PT: Research Funding: AbbVie, Pharmacyclics, Genentech, Adaptive Biotechnologies; Consultancy: Janssen, Genentech, Adaptive Biotechnologies, AbbVie; Lecture fees: Janssen. XT: Consultant for Innate Pharma, AstraZeneca and Beigene; Advisor for AbbVie. CZ: Research funding to University of Rochester from Acerta/AstraZeneca and TG Therapeutics. TZ: Roche, Innate, Incyte, AbbVie, Gilead, Janssen (honoraria). PLZ: Advisory Board Member: Secura Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, Beigene; Speakers Bureau: Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, Beigene; Consultant: MSD, Eusapharma, Novartis. BW: None reported. KR: None reported. MG: Consultant: Astra Zeneca, Pharmacyclics, Ascerta, Axio, Inc; Research Funding: Hairy Cell Leukemia Foundation for Patient Data Registry; Travel Expenses: Hairy Cell Leukemia Foundation; Scientific Board: Chair, Hairy Cell Leukemia Foundation Scientific Board (no reimbursement); and Scientific Honorarium: University of Pittsburgh.